Health Information Search Results
Peer Reviewed Scientific Research Reports.
|<< Prev 20 ||Showing 1 to 20 of 21 Matches||Next 20 >>|
1. Oncolytic viral therapy by bladder instillation using an E1A, E1B double-restricted adenovirus in an orthotopic bladder cancer model.
Match Strength: 10.035
OBJECTIVES: To investigate the therapeutic effect of AxdAdB-3, a double-restricted oncolytic adenovirus harboring a mutant E1A and an E1B-55KD deletion, on human bladder cancer cell lines and the SCID mouse model of orthotopic bladder cancer. METHODS: The cytopathic effects of AxdAdB-3 were evaluated in several cell lines (YTS-1, YTS-3, T24, J82, 5637) derived from human bladder or ureteral cancer and in a normal bladder mucosa-derived cell line (HCV29) with AxCAlacZ (control) or AxE1AdB (E1B-55KD-defective adenovirus) or dl922-947 (E1A-mutated adenovirus). The efficacy of bladder instillation ... Read More »
» Published in Urology. 2006 Sep;68(3):674-81. Epub 2006 Sep 18.
2. A prospective study of fish, marine fatty acids, and bladder cancer risk among men and women (United States).
Match Strength: 9.164
OBJECTIVE: To evaluate prospectively the association between intakes of fish, marine fatty acids, and bladder cancer risk in two ongoing cohorts, the Health Professionals Follow-up Study and the Nurses' Health Study. METHODS: During 16 and 18 years of follow-up, 501 and 235 incident cases of bladder cancer were diagnosed among men and women, respectively. Cox proportional hazard models were used to estimate incidence rate ratios (RR) and 95% confidence intervals (CI) between fish intake and bladder cancer risk adjusting for age, total caloric intake, pack-years of cigarette smoking, and ... Read More »
» Published in Cancer Causes Control. 2006 Nov;17(9):1163-73.
3. Human papilloma virus and p53 expression in bladder cancer in Egypt: relationship to schistosomiasis and clinicopathologic factors.
Match Strength: 8.541
The aim of the current study was to compare the role of p53 and human papillomavirus (HPV) in schistosomiasis-related and schistosomiasis-unrelated carcinoma of the urinary bladder. To achieve this aim, we investigated 114 bladder carcinomas for p53 oncoprotein expression by immunohistochemistry and for human papillomavirus by in situ hybridization technique. The results revealed that 64 tumors (56.1%) were schistosomiasis-associated. Sixty seven (58.8%) were transitional cell carcinomas and 32 (28%) were squamous cell carcinomas. The remaining 15 tumors (13.2%) included adenocarcinomas and ... Read More »
» Published in Pathol Oncol Res. 2006;12(3):173-8. Epub 2006 Sep 23.
4. Clinical model of lifetime cost of treating bladder cancer and associated complications.
Match Strength: 8.485
OBJECTIVES: To estimate the lifetime cost of bladder cancer and the contribution of complications to the total costs. METHODS: We reviewed the medical records of a retrospective cohort of 208 patients with bladder cancer who registered at our comprehensive cancer center from 1991 to 1999. We multiplied the number of resources used during management of bladder cancer by their unit charges. We converted charges into costs using the Medicare cost-to-charge ratio and inflated these to 2005 U.S. dollars. We estimated future costs by creating two extreme hypothetical scenarios. In the best-case ... Read More »
» Published in Urology. 2006 Sep;68(3):549-53. Epub 2006 Sep 18.
5. Radical cystectomy with ultrasound-guided partial prostatectomy for bladder cancer: a complication-preventing concept.
Match Strength: 7.390
OBJECTIVES: Radical cystectomy has been the reference standard for the treatment of muscle-invasive bladder cancer. However, this kind of therapy does have an impact on the patient's quality of life. For this reason, we performed prostate-sparing surgery during radical cystectomy without compromising the oncologic outcome. METHODS: From December 2003 to August 2005, 31 patients with a mean age of 63.6 +/- 8 years (range 48 to 79) underwent apex-sparing radical cystoprostatectomy for invasive bladder cancer. All patients underwent transurethral biopsy in the prostatic urethra to exclude ... Read More »
» Published in Urology. 2006 Sep;68(3):554-9. Epub 2006 Sep 18.
6. Bladder cancer 2000: molecular markers for the diagnosis of transitional cell carcinoma.
Match Strength: 7.092
The search continues for better tumor markers to improve the rate of detection of transitional cell carcinoma (TCC) more quickly in larger populations and to predict the possibility of disease recurrence. Among several new tests currently being screened, telomerase and hyaluronic acid/hyaluronidase (HA/HAase) have shown sensitivity and specificity equal to or better than cytology, and other promising tumor markers are being investigated. Although no marker has yet replaced the need to perform cystoscopy and cytology, the new tests can minimize the cost and difficulty of screening and long-term ... Read More »
» Published in Rev Urol. 2001 Spring;3(2):85-93.
7. LRIG1, a candidate tumour-suppressor gene in human bladder cancer cell line BIU87.
Match Strength: 6.882
OBJECTIVES: To determine the effects of LRIG1 on the growth, migration and invasion of bladder cancer cells and the mechanisms underlying such effects. MATERIALS AND METHODS: The plasmid pLRIG1-green fluorescence protein (GFP) was transfected into BIU87 bladder cancer cells by Lipofectamine2000 (Invitrogen, Groningen, the Netherlands), and the cells that expressed LRIG1 stably were screened out by G418. The changes in LRIG1 and epidermal growth factor receptor (EGFR) protein levels were measured by Western blot; growth curves were estimated by the tetrazolium (MTT) assay; then cell-cell ... Read More »
» Published in BJU Int. 2006 Oct;98(4):898-902.
8. Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy.
Match Strength: 6.699
OBJECTIVES: To describe the cancer-specific outcomes of patients with pathologic carcinoma in situ (CIS) only at radical cystectomy. METHODS: The records of 812 consecutive patients who underwent radical cystectomy and pelvic lymphadenectomy for bladder transitional cell carcinoma at three U.S. academic centers were reviewed. Of the 812 patients, 99 (12%) had CIS only at radical cystectomy. RESULTS: The distribution of clinical stage for the 99 patients with CIS only at radical cystectomy was as follows: 47% of patients had CIS only, 8% had cT1, 15% had cT1 plus CIS, 10% had cT2, 13% had cT2 ... Read More »
» Published in Urology. 2006 Sep;68(3):538-42. Epub 2006 Sep 18.
9. Silent urothelial cancer detected by sonography after renal transplantation.
Match Strength: 6.595
OBJECTIVES: Organ transplantation increases the incidence of cancer through unclear mechanisms. In our observation, urothelial cancer happens much more frequently in Chinese people. We reviewed the detection of urothelial cancer in our series after renal transplantation. METHODS: From July 1981 to June 2005, we performed 620 renal transplantations. We do graft and native kidney sonography survey annually even if the patient is asymptomatic. During this period, 10 urothelial tumors were detected. Herein we have reviewed the findings in these cases, along with their management and outcomes. ... Read More »
» Published in Transplant Proc. 2006 Sep;38(7):2084-5.
10. Cell-nuclear data reduction and prognostic model selection in bladder tumor recurrence.
Match Strength: 6.483
OBJECTIVE: The paper aims at improving the prediction of superficial bladder recurrence. To this end, feedforward neural networks (FNNs) and a feature selection method based on unsupervised clustering, were employed. MATERIAL AND METHODS: A retrospective prognostic study of 127 patients diagnosed with superficial urinary bladder cancer was performed. Images from biopsies were digitized and cell nuclei features were extracted. To design FNN classifiers, different training methods and architectures were investigated. The unsupervised k-windows (UKW) and the fuzzy c-means clustering algorithms ... Read More »
» Published in Artif Intell Med. 2006 Nov;38(3):291-303. Epub 2006 Sep 27.
11. A case of TURBT after penile prosthesis implantation.
Match Strength: 6.168
The patient was a 66-year-old man who had undergone implantation of a penile prosthesis for organic erectile dysfunction 7 years prior to consulting our hospital with a complaint of gross hematuria. Since a pedunculated, superficial tumor 1 cm in diameter was noted lateral to the left ureteral orifice, transurethral resection of the bladder tumor (TURBT) was performed. In this patient, we were able to insert the sheath with no difficulty, and the surgical procedure was done smoothly, resulting in complete resection of the tumor. However, the location of the tumor in the anterior or posterior ... Read More »
» Published in Hinyokika Kiyo. 2006 Aug;52(8):629-32.
12. Removal of more lymph nodes may provide better outcome, as well as more accurate pathologic findings, in patients with bladder cancer--analysis of role of pelvic lymph node dissection.
Match Strength: 5.962
OBJECTIVES: To examine the role of pelvic lymph node dissection (PLND) in patients who underwent radical cystectomy for bladder cancer. The diagnostic and therapeutic role of PLND is still controversial in bladder cancer. The extent of PLND and the necessary number of lymph nodes to remove have not been defined. METHODS: This retrospective review included 146 patients with refractory superficial and muscle-invasive disease treated with radical cystectomy, regional PLND (internal iliac, external iliac, and obturator nodes) and urinary diversion from January 1990 to December 2002. RESULTS: Lymph ... Read More »
» Published in Urology. 2006 Sep;68(3):543-8. Epub 2006 Sep 18.
13. Cancer incidence in first-degree relatives of a population-based set of cases of early-onset breast cancer.
Match Strength: 5.354
Reliable determination of familial risks for cancer is important for clinical counselling, cancer prevention and understanding cancer aetiology. Family-based gene identification efforts may be targeted if the risks are well characterised and the mode of inheritance is identified. Early-onset breast cancer in a family member is a risk indicator for cancer among first-degree relatives; however, the familial risk pattern has not been assessed fully in population-based incidence studies. We estimated the risks for cancers of the breast, ovary and other sites among the first-degree relatives of ... Read More »
» Published in Eur J Cancer. 2006 Nov;42(17):3034-40. Epub 2006 Sep 22.
14. Precise anatomy of the vesico-uterine ligament for radical hysterectomy.
Match Strength: 4.932
OBJECTIVES: To clarify the anatomy of the vesico-uterine ligament (VUL), we meticulously separated the VUL under magnification (x2.5) during Okabayashi's radical hysterectomy. METHODS: Fifty-nine patients (TNM nomenclature: pTIb: 39, pT2a: 5, pT2b: 7, after trans-arterial anticancer-drug infusion treatment for the cervical cancer: 8) underwent this meticulous operation. Blood loss was recorded at two separate time points: during the separation of the VUL and after removal of the uterus. RESULTS: After complete separation of the uterine artery and superficial uterine vein from the ureter, we ... Read More »
» Published in Gynecol Oncol. 2007 Jan;104(1):186-91. Epub 2006 Sep 22.
15. Effect of pH and human serum albumin on the cytotoxicity of a glucuronide prodrug of 9-aminocamptothecin.
Match Strength: 4.861
PURPOSE : 9-aminocamptothecin glucuronide (9ACG) is a prodrug of 9-aminocamptothecin (9AC) that displays potent antitumor activity against human tumor xenografts in nude mice. Camptothecins exist in a pH dependent equilibrium between active lactone and inactive carboxy forms that can be altered by binding to human serum albumin (HSA). Here we investigated the influence of pH and HSA on the lactone-carboxy equilibrium, HSA binding, and cytotoxicity of 9ACG. METHODS : Microfiltration and HPLC were used to measure the influence of pH on lactone to carboxy conversion and HSA binding of 9ACG as ... Read More »
» Published in Cancer Chemother Pharmacol. 2006 Sep 16;
16. Comparison of 2D vs. 3D dosimetry for Rotte 'Y' applicator high dose rate brachytherapy for medically inoperable endometrial cancer.
Match Strength: 4.758
The purpose of our research is to compare CT-based volumetric calculations and International Commission on Radiation Units and Measurements (ICRU) reference-point estimates of radiation doses to the target volume, bladder, rectum, and sigmoid colon in patients with carcinoma of the endometrium treated with high dose rate intracavitary Rotte 'Y' applicator brachytherapy (HDRB). Eleven patients with cancer of the endometrium were treated with CT-compatible HDR intracavitary Rotte 'Y' applicators (Nucletron) and underwent post-implant pelvic CT scans with applicators in place. All patients were ... Read More »
» Published in Technol Cancer Res Treat. 2006 Oct;5(5):521-7.
17. Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma.
Match Strength: 4.507
PURPOSE: Vaccination against human cancer is a promising therapeutic approach but the optimal antigen or antigens remain undefined. Cancer-testis antigens (CTA), a family of tumor-associated antigens, have both potent immunogenicity and restricted expression patterns in normal adult tissues, highly desirable characteristics for targets of anticancer vaccines. These antigens were evaluated for both the degree of expression and prognostic value in cancer of the urothelium. EXPERIMENTAL DESIGN: The expression patterns of nine CTAs (NY-ESO-1, LAGE-1, MAGE-A1, MAGE-A3, MAGE-A4, MAGE-A10, CT7, CT10, ... Read More »
» Published in Clin Cancer Res. 2006 Sep 15;12(18):5442-7.
18. Radical cystectomy with extended lymphadenectomy in the presence of a pelvic kidney.
Match Strength: 4.200
The pelvic kidney represents the most common form of congenital renal ectopia. Because of its location, variable vasculature, and short ureteral length, the presence of a pelvic kidney in a patient undergoing radical cystectomy and pelvic lymphadenectomy creates unique technical challenges for the urologic surgeon. We describe a patient with a right pelvic kidney and invasive bladder cancer for whom radical cystectomy with extended pelvic iliac lymph node dissection and ileal conduit was performed. Publication Types: Case ... Read More »
» Published in Urology. 2006 Sep;68(3):672.e21-2. Epub 2006 Sep 18.
19. The 'pitcher pot' ileal neobladder: early experiences.
Match Strength: 2.778
OBJECTIVE: To analyse initial results of newly designed ileal neobladder-a modification of Studer neobladder METHODS: Twenty-four patients with urinary bladder cancer underwent radical cystoprostatectomy from February 2005 to March 2006. Twenty-one of them had urinary diversion using ileal neobladder in spherical configuration with ileal neourethra (giving the shape of an inverted Indian earthenware container called a 'pitcher pot') to circumvent the problem of short mesentery and construct a low-pressure spherical ileal neobladder. RESULTS: Early post-operative complications occurred in 42% ... Read More »
» Published in Jpn J Clin Oncol. 2006 Nov;36(11):717-22. Epub 2006 Sep 26.
20. Template-driven gene selection procedure.
Match Strength: 2.706
The hierarchical clustering and statistical techniques usually used to analyse microarray data do not inherently represent the underlying biology. Herein, a hybrid approach involving characteristics of both supervised and unsupervised learning is presented. This approach is based on template matching in which the interaction of the variables of inherent malignancy and the ability to express the malignant phenotype are modelled. Immortalised normal urothelial cells and bladder cancer cells of different malignancy were grown in conventional two-dimensional tissue culture and in three dimensions ... Read More »
» Published in Syst Biol (Stevenage). 2006 Jan;153(1):4-12.
|<< Prev 20 ||Showing results 1 to 20 of 21||Next 20 >>|
* All information on Level1Diet.com is for educational purposes only. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. Before changing your diet, or adding supplements to your diet, or beginning an exercise program, everyone should consult a qualified and licensed health practitioner; a physician, dietician or similar professional.